De hemmelige “zombiecelle”-dræbere: Niche-senolytiske lægemidler, der bekæmper aldringens ur
A Mayo Clinic-led phase 2 trial in 2024 found dasatinib plus quercetin modestly increased wrist bone density in older women with high senescent cell burden. Unity Biotechnology’s foselutoclax improved vision in diabetic macular edema patients. About 20 clinical trials of senolytics were ongoing worldwide as of 2024–2025. Results for Alzheimer’s disease are expected in 2025.